Risperidone alters food intake, core body temperature, and locomotor activity in mice

Department of Biostatistics, University of Alabama at Birmingham, United States
Physiology & Behavior (Impact Factor: 3.03). 03/2009; 96(3):457-463. DOI: 10.1016/j.physbeh.2008.11.011

ABSTRACT Risperidone induces significant weight gain in female mice; however, the underlying mechanisms related to this effect are unknown. We investigated the effects of risperidone on locomotor activity, core body temperature, and uncoupling protein (UCP) and hypothalamic orexin mRNA expression. Female C57BL/6J mice were acclimated to individual housing and randomly assigned to either risperidone (4 mg/kg BW day) or placebo (PLA). Activity and body temperature were measured over 48-hour periods twice a week for 3 weeks. Food intake and body weights were measured weekly. UCP1 (BAT), UCP3 (gastrocnemius), and orexin (hypothalamus) mRNA expressions were measured using RT-PCR. Risperidone-treated mice consumed more food (p = 0.050) and gained more weight (p = 0.0001) than PLA-treated mice after 3 weeks. During the initial 2 days of treatment, there was an acute effect of treatment on activity (p = 0.046), but not body temperature (p = 0.290). During 3 weeks of treatment, average core body temperatures were higher in risperidone-treated mice compared to controls during the light phase (p = 0.0001), and tended to be higher during the dark phase (p = 0.057). Risperidone-treated mice exhibited lower activity levels than controls during the dark phase (p = 0.006); there were no differences in activity during the light phase (p = 0.47). UCP1 (p < 0.01) and UCP3 (p < 0.05) mRNA expressions were greater in risperidone-treated mice compared to controls, whereas, orexin mRNA expression was lower in risperidone-treated mice (p < 0.01). These results suggest that risperidone-induced weight gain in mice is a consequence of increased energy intake and reduced activity, while the elevation in body temperature may be a result of thermogenic effect of food intake and elevated UCP1, UCP3, and a reduced hypothalamic orexin expression.

Download full-text


Available from: Patricia Jumbo-Lucioni, Jul 26, 2015
  • Source
    • "A number of studies have also indicated that risperidone administration in rats through different routes increased food intake and body weight in a four-week period (Baptista et al., 2002; Ota et al., 2002, Cope et al., 2005; Pouzet et al., 2003; Davoodi et al., 2009). Previous studies have found that animals in the risperidone group consumed more food compared to the vehicle group, which may have caused increased adipose tissue mass and subsequent obesity (Cope et al., 2009). In addition, plasma leptin levels increased in the risperidone group compared with the vehicle group. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the use of atypical antipsychotic drugs has been successful in the treatment of schizophrenia, they can cause some complications in the long-term use, including weight gain. Patients using these drugs tend to disrupt treatment primarily due to side effects. The atypical antipsychotic mechanism of action regulates a number of highly disrupted neurotransmitter pathways in the brains of psychotic patients but may also cause impairment of neurohormonal pathways in different brain areas. In this study, we investigated the circulating levels of hypothalamic neurohormones, which are related to appetite regulation; neuropeptide Y (NPY); alpha melanocyte stimulating hormone (α-MSH); cocaine and amphetamine regulated transcript (CART); agouti-related peptide (AgRP); and leptin in male Wistar rats, which were treated with risperidone, a serotonin antagonist, for four weeks. Alterations in the mRNA expression levels of these candidate genes in the hypothalamus were also analyzed. We hypothesized that risperidone treatment might alter both hypothalamic and circulating levels of neuropeptides through serotonergic antagonism, resulting in weight gain. Gene expression studies revealed that the mRNA expression levels of proopiomelanocortin (POMC), AgRP, and NPY decreased as well as their plasma levels, except for NPY. Unexpectedly, CART mRNA levels increased when their plasma levels decreased. Because POMC neurons express the serotonin receptor (5HT2C), the serotonergic antagonism of risperidone on POMC neurons may cause an increase in appetite and thus increase food consumption even in a short-term trial in rats. Copyright © 2014 Elsevier B.V. All rights reserved.
    Brain Research 11/2014; 1596. DOI:10.1016/j.brainres.2014.10.070 · 2.83 Impact Factor
  • Source
    • "The significantly increased food intake in only PAL-treated group might be due to its action through histamine H 1 receptor (Kim et al., 2007). Several AAPDs such as RIS and olanzapine increased the food intake in rodents (Cope et al., 2009; Davoodi et al., 2009). Prenatally LPSexposed neonates showed varied types of abnormalities in reflex responses. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Studies on animal models provide enough evidences that old age appearance of psychosis on exposures to various insults during critical period of brain development could be prevented on antipsychotic drug treatment. Presently, gestational intervention of the atypical antipsychotic paliperidone (PAL) was done along with the exposure of bacterial endotoxin lipopolysaccharide/LPS hypothesizing that the drug would counteract and/or prevent the immune activation-induced behavioral deficits in mice. Effect of the PAL (0.05mg/kg; GD 15-PND 28) in preventing reflex, sensorimotor and anxiety deficits in prenatally LPS-challenged (800µg/kg; GD 15 and GD 17) mice was assessed at three different life stages: neonatal (PND 4-PND 14), adolescence (PND 35) and at adulthood (PND 85). LPS-induced behavioral deficits were recognizable even at neonatal and adolescence stages, though more pronounced at adulthood. In only PAL-treated group few behavioral deficits though observed both at neonatal and adult stages but less prominent than LPS group. PAL co-treatment prevented the abnormalities in nest-seeking behavior in neonates, anxiety abnormalities at adolescence and adulthood but not the sensorimotor impairment. The drug might have maintained the stress homeostasis to counteract the behavioral abnormalities as LPS-induced hypercorticosteronemia was prevented on PAL co-treatment. In view of the in utero exposure, comparatively low drug dose was selected. Though efficacy has been predicted, the dose was not effective to prevent all psychopathological impairments. Considering the wider objectives, it was not possible to conduct multi dose study simultaneously. Our ongoing study with higher dose may predict the effective PAL dose in prevention of psychiatric illness.
    European Journal of Pharmacology 09/2014; 747. DOI:10.1016/j.ejphar.2014.09.011 · 2.68 Impact Factor
  • Source
    • "Limitations of the present study include any psychotropic medication administered, but elevations of hcrt-1 are only reported for sertraline and risperidone, which we've prescribed each in one patient (Salomon et al., 2003; Cope et al., 2009). Furthermore, the design of the study did not consider the locomotor activity prior to lumbar puncture. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Depressive patients exhibit symptoms of impaired regulation of wakefulness with hyperarousal and agitation as well as difficulties to falling asleep and preserving sleep continuity. Changes in hypocretin (hcrt) levels as polypeptides with impact on arousal and sleep-wake-regulation have been discussed in affective disorders but have not been investigated in patients with solely unipolar depression in comparison to healthy controls. In the present study, cerebrospinal fluid (CSF) levels of hcrt-1 for the first time were analyzed in patients with major depressive disorder (MDD) without psychiatric comorbidities and compared with levels in healthy controls. In 17 inpatients with MDD (mean Hamilton Depression Rating Scale 13.9 ± 7.4) and 10 healthy controls, CSF-hcrt-1 levels were measured using a fluorescence immunoassay (FIA). The mean hcrt-1 CSF levels in patients with MDD (74.3 ± 17.8pg/ml) did not differ compared to that of healthy controls (82.8 ± 22.1pg/ml). Hcrt-1 levels did not correlate with the severity of depressive episode, the symptoms of depression or the number of episodes. Although autonomic and neurohumoral signs of hyperarousal are common in MDD, hcrt-1 levels in CSF were not found to be altered in MDD compared to healthy controls. Whether hcrt-1 levels are altered in depressive patients exhibiting impaired vigilance regulation has to be investigated in further studies combining measures of CSF-hcrt-1 with electroencephalography.
    Psychiatry Research 07/2011; 190(2-3):240-3. DOI:10.1016/j.psychres.2011.06.004 · 2.68 Impact Factor
Show more